TIA、脑卒中患者血清MMP-1、MMP-3、MMP-9的表达水平
|
摘要
目的分析短暂性脑缺血性发作(TIA)和脑卒中患者血清基质金属蛋白酶-1(MMP-1)、MMP-3、MMP-9的表达水平。方法本研究选取2016年1月至2017年1月收治的TIA患者100例(TIA组),急性脑卒中患者100例(卒中组),健康体检患者100例(对照组)为研究对象。分析三组研究对象的一般资料,MMP-1、MMP-3、MMP-9基因表达与水平及其相关性。结果 TIA组、卒中组患者在性别、年龄、体质指数(BMI)、糖尿病史及饮酒史与对照组比较,差异无统计学意义(P>0.05),而吸烟史、高血压病史与对照组比较差异具有统计学意义(P<0.05)。TIA组、卒中组患者的血清MMP-1分别为(123.31±8.20)μg/L和(87.12±5.27)μg/L、MMP-3分别为(93.31±8.15)μg/L和(57.64±5.24)μg/L、MMP-9分别为(133.31±8.89)μg/L和(109.56±5.13)μg/L,水平均高于对照组,差异均有统计学意义(P<0.05)。TIA组、卒中组患者的MMP-1基因、MMP-9基因中基因型T/T与等位基因频率T均高于对照组,差异均有统计学意义(P<0.05)。TIA组、卒中组患者的MMP-3基因中基因型6A/6A与等位基因频率6A均高于对照组,差异有统计学意义(P<0.05)。MMP-1、MMP-3、MMP-9水平增高均是TIA组、卒中组患者的独立危险因素,差异有统计学意义(P<0.05)。结论 MMP-1、MMP-3、MMP-9水平检测有助于TIA、脑卒中诊断,且其主要基因位点突变与TIA、脑卒中发生相关,可为临床预防及治疗提供重要指导。
Objective To analyze the expression of serum matrix metalloproteinase-1(MMP-1),MMP-3 and MMP-9 in transient ischemic attack(TIA)and stroke patients. Methods 100 cases with TIA(TIA group),100 cases with acute stroke(stroke group)and 100 healthy individuals(control group)from January 2016 to January 2017 were selected as study subjects.The expression levels of MMP-1,MMP-3,MMP-9 and the correlation between the expression of MMP-1 and MMP-9 were analyzed. Results There was no significant difference of the sex,age,body mass index(BMI),history of diabetes mellitus and alcohol consumption between the TIA group,stroke group and the control group(P>0.05). The history of smoking,history of hypertension of the TIA group,stroke group and the control group were significantly different(P<0.05). The levels of serum MMP-1 were(123.31±8.20)μg/L and(87.12±5.27)μg/L,MMP-3 were(93.31±8.15)μg/L and(57.64±5.24)μg/L,and MMP-9 were(133.31±8.89)μg/L and(109.56±5.13)μg/L in TIA group and stroke group respectively,which were higher than those in control group(P<0.05). The genotype T/T and allele frequency of MMP-1 gene and MMP-9 in TIA group and stroke group were significantly higher than those in control group(P<0.05). The genotype 6 A/6 A and allele frequency of MMP-3 gene in TIA group and stroke group were higher than those in control group(P<0.05). The levels of MMP-1,MMP-3 and MMP-9 were independent risk factors in TIA group and stroke group(P<0.05). Conclusion The levels of MMP-1,MMP-3 and MMP-9 have early diagnosis value for TIA and stroke,and its main gene mutation can predict the incidence of cerebrovascular disease which could provide guidance for clinical prevention and treatment.
Objective To analyze the expression of serum matrix metalloproteinase-1(MMP-1),MMP-3 and MMP-9 in transient ischemic attack(TIA)and stroke patients. Methods 100 cases with TIA(TIA group),100 cases with acute stroke(stroke group)and 100 healthy individuals(control group)from January 2016 to January 2017 were selected as study subjects.The expression levels of MMP-1,MMP-3,MMP-9 and the correlation between the expression of MMP-1 and MMP-9 were analyzed. Results There was no significant difference of the sex,age,body mass index(BMI),history of diabetes mellitus and alcohol consumption between the TIA group,stroke group and the control group(P>0.05). The history of smoking,history of hypertension of the TIA group,stroke group and the control group were significantly different(P<0.05). The levels of serum MMP-1 were(123.31±8.20)μg/L and(87.12±5.27)μg/L,MMP-3 were(93.31±8.15)μg/L and(57.64±5.24)μg/L,and MMP-9 were(133.31±8.89)μg/L and(109.56±5.13)μg/L in TIA group and stroke group respectively,which were higher than those in control group(P<0.05). The genotype T/T and allele frequency of MMP-1 gene and MMP-9 in TIA group and stroke group were significantly higher than those in control group(P<0.05). The genotype 6 A/6 A and allele frequency of MMP-3 gene in TIA group and stroke group were higher than those in control group(P<0.05). The levels of MMP-1,MMP-3 and MMP-9 were independent risk factors in TIA group and stroke group(P<0.05). Conclusion The levels of MMP-1,MMP-3 and MMP-9 have early diagnosis value for TIA and stroke,and its main gene mutation can predict the incidence of cerebrovascular disease which could provide guidance for clinical prevention and treatment.
引文
[1]Zhang C,Chen L,Gu Y.Polymorphisms of MMP-1,and MMP-3,and susceptibility to rheumatoid arthritis.A meta-analysis[J].Z Rheumatol,2015,74(3):258-262.
[2]王艳红,李立明.1990-2010年我国城乡成年人群脑血管疾病死亡率的流行趋势[J].中华疾病控制杂志,2013,17(3):185-189.Wang YH,Li LM.Trends in cerebrovascular disease mortality in China between 1990-2010[J].Chin J Dis Control Prev,2013,17(3):185-189.
[3]李丽.血清基质金属蛋白酶-9、神经烯醇化酶检测在急性脑梗死的临床应用研究[J].中国实验诊断学,2014,18(7):1089-1090.Li L.Clinical application of serum matrix metalloproteinase-9 and neuro enolase in acute cerebral infarction[J].Chin J Lab Diagn,2014,18(7):1089-1090.
[4]饶明俐.中国脑血管病防治指南[M].北京:人民卫生出版社,2007.Rao ML.Guidelines for prevention and treatment of cerebrovascular disease in China[M].Beijing:People′s Medical Publishing House,2007.
[5]周皖舒,彭年春,时立新,等.贵阳地区60岁以上老年人群心脑血管疾病危险因素研究[J].贵州医科大学学报,2016,41(8):935-938,950.Zhou WS,Peng NC,Shi LX,et al.Risk factors of cardiocerebro vascular disease in elderly people aged 60 years or above in Guiyang city[J].Journal of Guizhou Medical University,2016,41(8):935-938,950.
[6]李杰华.进展性缺血性脑卒中研究进展[J].医学理论与实践,2016,29(12):1565-1567.Li JH.Progress in progressive ischemic stroke[J].J Med Theor&Prac,2016,29(12):1565-1567.
[7]Zeng GQ,Chen AB,Li W,et al.High MMP-1,MMP-2,and MMP-9 protein levels in osteoarthritis[J].Genet Mol Res,2015,14(4):14811-14822.
[8]张津华,马丽丽,李江坤,等.糖尿病合并脑梗死患者外周血T淋巴细胞亚群与基质金属蛋白酶9的相关性[J].中华老年心脑血管病杂志,2015,17(1):67-69.Zhang JH,Ma LL,Li JK,et al.Association between peripheral T lymphocyte subpopulation and MMP-9 in diabetes patients with ischemic stroke[J].Chin J Geriatr Heart Brain Vessel Dis,2015,17(1):67-69.
[9]V?lim?ki J,Uusitalo H.Matrix metalloproteinases(MMP-1,MMP-2,MMP-3 and MMP-9,and TIMP-1,TIMP-2 and TIMP-3)and markers for vascularization in functioning and nonfunctioning bleb capsules of glaucoma drainage implants[J].Acta Ophthalmol,2015,93(5):450-456.
[10]Ricci S,Bruzzese D,DI Carlo A.Evaluation of MMP-2,MMP-9,TIMP-1,TIMP-2,NGAL and MMP-9/NGAL complex in urine and sera from patients with bladder cancer[J].Oncol Lett,2015,10(4):2527-2532.
[11]陈建雅,钟望涛.基质金属蛋白酶-9与脑血管动脉粥样硬化的相关性[J].神经疾病与精神卫生,2015,15(5):530-532.Chen JY,Zhong WT.Research progress on the relationship between MMP-9 and cerebrovascular atherosclerosis[J].Journal of Neuroscience and Mental Health,2015,15(5):530-532.
[12]Sharma OP,Agrawal S,Kumar MS.Physicochemical properties of the modeled structure of astacin metalloprotease moulting enzyme NAS-36 and mapping the druggable allosteric space of Heamonchus contortus,Brugia malayi and Ceanorhabditis elegans via molecular dynamics simulation[J].Interdiscip Sci,2013,5(4):312-323.
[13]Ren S,Qian S,Wang W,et al.Prospective study of sarpogrelate hydrochloride on patients with arteriosclerosis obliterans[J].Ann Thorac Cardiovasc Surg,2013,19(1):30-34.
[14]Naylor AR.Thrombolysis and expedited carotid revascularization[J].J Cardiovas Surg,2015,56(2):159-164.
[15]France DJ,Stepek G,Houston DR,et al.Identification and activity of inhibitors of the essential nematode-specific metalloprotease DPY-31[J].Bioorg Med Chem Lett,2015,25(24):5752-5755.
[16]Du X,Lin BC,Wang QR,et al.MMP-1 and Pro-MMP-10 as potential urinary pharmacodynamic biomarkers of FGFR3-targeted therapy in patients with bladder cancer[J].Clin Cancer Res,2014,20(24):6324-6335.
[17]Kreisel SH,Stroick M,Griebe M,et al.True Effects or Bias?MMP-2 and MMP-9 serum concentrations after acute stroke[J].Cerebrovasc Dis,2016,42(5-6):352-360.
[18]Fang X,Tao D,Shen J,et al.Neuroprotective effects and dynamic expressions of MMP-9 and TIMP1 associated with atorvastatin pretreatment in ischemia-reperfusion rats[J].Neurosci Lett,2015,603:60-65.
[19]刘洁,王前,郭艳敏.细胞间黏附分子-1基因469K/E多态性与动脉粥样硬化血栓形成性脑卒中的相关性[J].热带医学杂志,2015,15(5):642-645.Liu J,Wang Q,Guo YM.Relationship between 469K/E polymorphism of the ICAM-1 gene and atherothrombosis ischemic stroke(AIS)[J].J Trop Med,2015,15(5):642-645.
[2]王艳红,李立明.1990-2010年我国城乡成年人群脑血管疾病死亡率的流行趋势[J].中华疾病控制杂志,2013,17(3):185-189.Wang YH,Li LM.Trends in cerebrovascular disease mortality in China between 1990-2010[J].Chin J Dis Control Prev,2013,17(3):185-189.
[3]李丽.血清基质金属蛋白酶-9、神经烯醇化酶检测在急性脑梗死的临床应用研究[J].中国实验诊断学,2014,18(7):1089-1090.Li L.Clinical application of serum matrix metalloproteinase-9 and neuro enolase in acute cerebral infarction[J].Chin J Lab Diagn,2014,18(7):1089-1090.
[4]饶明俐.中国脑血管病防治指南[M].北京:人民卫生出版社,2007.Rao ML.Guidelines for prevention and treatment of cerebrovascular disease in China[M].Beijing:People′s Medical Publishing House,2007.
[5]周皖舒,彭年春,时立新,等.贵阳地区60岁以上老年人群心脑血管疾病危险因素研究[J].贵州医科大学学报,2016,41(8):935-938,950.Zhou WS,Peng NC,Shi LX,et al.Risk factors of cardiocerebro vascular disease in elderly people aged 60 years or above in Guiyang city[J].Journal of Guizhou Medical University,2016,41(8):935-938,950.
[6]李杰华.进展性缺血性脑卒中研究进展[J].医学理论与实践,2016,29(12):1565-1567.Li JH.Progress in progressive ischemic stroke[J].J Med Theor&Prac,2016,29(12):1565-1567.
[7]Zeng GQ,Chen AB,Li W,et al.High MMP-1,MMP-2,and MMP-9 protein levels in osteoarthritis[J].Genet Mol Res,2015,14(4):14811-14822.
[8]张津华,马丽丽,李江坤,等.糖尿病合并脑梗死患者外周血T淋巴细胞亚群与基质金属蛋白酶9的相关性[J].中华老年心脑血管病杂志,2015,17(1):67-69.Zhang JH,Ma LL,Li JK,et al.Association between peripheral T lymphocyte subpopulation and MMP-9 in diabetes patients with ischemic stroke[J].Chin J Geriatr Heart Brain Vessel Dis,2015,17(1):67-69.
[9]V?lim?ki J,Uusitalo H.Matrix metalloproteinases(MMP-1,MMP-2,MMP-3 and MMP-9,and TIMP-1,TIMP-2 and TIMP-3)and markers for vascularization in functioning and nonfunctioning bleb capsules of glaucoma drainage implants[J].Acta Ophthalmol,2015,93(5):450-456.
[10]Ricci S,Bruzzese D,DI Carlo A.Evaluation of MMP-2,MMP-9,TIMP-1,TIMP-2,NGAL and MMP-9/NGAL complex in urine and sera from patients with bladder cancer[J].Oncol Lett,2015,10(4):2527-2532.
[11]陈建雅,钟望涛.基质金属蛋白酶-9与脑血管动脉粥样硬化的相关性[J].神经疾病与精神卫生,2015,15(5):530-532.Chen JY,Zhong WT.Research progress on the relationship between MMP-9 and cerebrovascular atherosclerosis[J].Journal of Neuroscience and Mental Health,2015,15(5):530-532.
[12]Sharma OP,Agrawal S,Kumar MS.Physicochemical properties of the modeled structure of astacin metalloprotease moulting enzyme NAS-36 and mapping the druggable allosteric space of Heamonchus contortus,Brugia malayi and Ceanorhabditis elegans via molecular dynamics simulation[J].Interdiscip Sci,2013,5(4):312-323.
[13]Ren S,Qian S,Wang W,et al.Prospective study of sarpogrelate hydrochloride on patients with arteriosclerosis obliterans[J].Ann Thorac Cardiovasc Surg,2013,19(1):30-34.
[14]Naylor AR.Thrombolysis and expedited carotid revascularization[J].J Cardiovas Surg,2015,56(2):159-164.
[15]France DJ,Stepek G,Houston DR,et al.Identification and activity of inhibitors of the essential nematode-specific metalloprotease DPY-31[J].Bioorg Med Chem Lett,2015,25(24):5752-5755.
[16]Du X,Lin BC,Wang QR,et al.MMP-1 and Pro-MMP-10 as potential urinary pharmacodynamic biomarkers of FGFR3-targeted therapy in patients with bladder cancer[J].Clin Cancer Res,2014,20(24):6324-6335.
[17]Kreisel SH,Stroick M,Griebe M,et al.True Effects or Bias?MMP-2 and MMP-9 serum concentrations after acute stroke[J].Cerebrovasc Dis,2016,42(5-6):352-360.
[18]Fang X,Tao D,Shen J,et al.Neuroprotective effects and dynamic expressions of MMP-9 and TIMP1 associated with atorvastatin pretreatment in ischemia-reperfusion rats[J].Neurosci Lett,2015,603:60-65.
[19]刘洁,王前,郭艳敏.细胞间黏附分子-1基因469K/E多态性与动脉粥样硬化血栓形成性脑卒中的相关性[J].热带医学杂志,2015,15(5):642-645.Liu J,Wang Q,Guo YM.Relationship between 469K/E polymorphism of the ICAM-1 gene and atherothrombosis ischemic stroke(AIS)[J].J Trop Med,2015,15(5):642-645.